An observational study to compare users of rebamipide ophthalmic solution with non-users among patients suffering from dacryocystitis with calculus

An observational study to compare users of rebamipide ophthalmic solution with non-users among patients suffering from dacryocystitis with calculus - An observational study to compare users of rebamipide ophthalmic solution with non-users among patients suffering from dacryocystitis with calculus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039339

Enrollment

Registered

2020-02-10

Start date

2020-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dacryocystitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are included in this study. 1) Male or female 2) Inpatients or ambulatory patients 3) Patients who are aged of 20 years or older when giving their consent 4) Patients who completed treatment of dacryocystitis accompanied with lacrimal sac calculi

Exclusion criteria

Exclusion criteria: Patients who fall into any of the following criteria are excluded from participating in the study. 1) Patients whose history of rebamipide ophthalmic solution use is unknown (within 2 years after onsent of main symptom caused by the dacryocystitis accompanied with lacrimal sac calculi in the eye to be investigated)

Design outcomes

Primary

Measure	Time frame
Gender Age, Birthdate Eye to be investigated The day of onset and type of dacryocystitis-related symptoms in the eye to be investigated (lacrimation, eye discharge, swelling, feeling of calculus, and others) Treatment, course, and outcome of lacrimal sac calculi in the eye to be investigated Use of rebamipide ophthalmic solution Medication (name of drug, purpose of use, usage and dose, date of the initial administration, date of completion of the administration) History of punctal plug use Complications (on eyes or systemic) History of lacrimal duct obstruction or dacryocystitis, period, and treatment Habit of smoking, daily number of cigarettes, years of smoking history Habit of alcohol drinking, type of alcohol, average daily intake Composition of lacrimal sac calculi in the eye to be investigated (rebamipide, protein, borate, and calcium phosphate) Bacterial culture and identification Dacryocystography Schirmer's test Corneal fluorescein staining DEQS (Dry Eye related Quality of life Score)	—

Measure

Time frame

Gender Age, Birthdate Eye to be investigated The day of onset and type of dacryocystitis-related symptoms in the eye to be investigated (lacrimation, eye discharge, swelling, feeling of calculus, and others) Treatment, course, and outcome of lacrimal sac calculi in the eye to be investigated Use of rebamipide ophthalmic solution Medication (name of drug, purpose of use, usage and dose, date of the initial administration, date of completion of the administration) History of punctal plug use Complications (on eyes or systemic) History of lacrimal duct obstruction or dacryocystitis, period, and treatment Habit of smoking, daily number of cigarettes, years of smoking history Habit of alcohol drinking, type of alcohol, average daily intake Composition of lacrimal sac calculi in the eye to be investigated (rebamipide, protein, borate, and calcium phosphate) Bacterial culture and identification Dacryocystography Schirmer's test Corneal fluorescein staining DEQS (Dry Eye related Quality of life Score)

—

Countries

Japan

Contacts

Public ContactHiroki Takayama

Soiken, Inc. Clinical Study Support Division

takayama@soiken.com0332951350

Outcome results